Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Inflammatory Bowel Diseases 1Crohn Disease 1

Interventions

Infliximab 3Tea 2Polyethylene Glycols 2Lidocaine 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2sodium phosphate 1purine 1prucalopride 1picosulfate sodium 1golimumab 1fumaric acid 1Sulfasalazine 1Pneumococcal Vaccines 1Passive Cutaneous Anaphylaxis 1Papillomavirus Vaccines 1Narrow Band Imaging 1Morphine 1Methotrexate 1Mesalamine 1Mercaptopurine 1MEDI2070 1Exercise 1Etanercept 1Dietary Supplements 1Diatrizoate Meglumine 1Diagnostic Imaging 1Calcium Dobesilate 1CT-P13 1Bupivacaine 1Bisacodyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Inflammatory Bowel Diseases × MEDI2070 × Clear all
NCT01714726 2021-05-26

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

AstraZeneca

Phase 2 Completed
121 enrolled 22 charts

Crohn Disease, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡